Infliximab beta

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 12:11:32 GMT 2025` Edited by `admin` on `Wed Apr 02 12:11:32 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG1\|KAPPA
Sequence Origin	MOUSE CHIMERIC
Sequence Type	COMPLETE
Record UNII	X95ZTP4AEK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

H-gamma1 heavy chain chimeric (1-450) [VH (Mus musculus IGHV6-6*02 (89.0%) -(IGHD) -IGHJ2*01 (92.9%), CDR-IMGT [8.10.11] (26-33.51-60.99-109)) (1-120) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219

Preferred Name

English

Infliximab beta

Official Name

English

Immunoglobulin G1, anti-(human tumor necrosis factor ?) (human-Mus musculus monoclonal XTMAB-16 ?1-chain), disulfide with human-Mus musculus monoclonal XTMAB-16 ?-chain, dimer

Common Name

English

immunoglobulin G1-kappa, anti-[Homo sapiens TNF (tumor necrosis factor, TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA)], chimeric monoclonal antibody (infliximab beta)

Common Name

English

infliximab beta [INN]

Common Name

English

HUMANIZED RECOMBINANT ANTI-TUMOR NECROSIS FACTOR ? MONOCLONAL ANTIBODY

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

782020

Created by admin on Wed Apr 02 12:11:32 GMT 2025 , Edited by admin on Wed Apr 02 12:11:32 GMT 2025

Code System Code Type Description

FDA UNII

X95ZTP4AEK

Created by admin on Wed Apr 02 12:11:32 GMT 2025 , Edited by admin on Wed Apr 02 12:11:32 GMT 2025

PRIMARY

CAS

2639475-46-8

Created by admin on Wed Apr 02 12:11:32 GMT 2025 , Edited by admin on Wed Apr 02 12:11:32 GMT 2025

PRIMARY

INN

13096

Created by admin on Wed Apr 02 12:11:32 GMT 2025 , Edited by admin on Wed Apr 02 12:11:32 GMT 2025

PRIMARY

From	To
1_22	1_98
2_22	2_98
2_147	2_203
2_223	4_214
2_264	2_324
1_147	1_203
2_370	2_428
3_23	3_88
3_134	3_194
4_23	4_88
4_134	4_194
1_223	3_214
1_229	2_229
1_232	2_232
1_264	1_324
1_370	1_428

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_300
N	2_300
N	3_41
N	4_41

Related Record Type Details


					4TVX2I407K

TUMOR NECROSIS FACTOR-.ALPHA. HUMAN (PLASMA DERIVED, SOLUBLE FORM)

TARGET -> INHIBITOR

Interaction Type:

IN-VIVO

Amount:

Related Record Type Details


					X95ZTP4AEK

Infliximab beta

ACTIVE MOIETY

Comments:

anti-[Homo sapiens

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID REMOVAL	[1_450] [2_450]	C-TERMINUS	K		LYSINE	K3Z4F929H6

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL